Pasar al contenido principal

REFORMULANDO EL METABOLISMO MEDIANTE LA IDENTIFICACION DE NUEVOS METABOLITOS Y REACCIONES BIOQUIMICAS UTILIZANDO UNA NUEVA HERRAMIENTA METABOLOMICA

BFU2014-57466-P

•
Nombre agencia financiadora Ministerio de Economía y Competitividad
Acrónimo agencia financiadora MINECO
Programa Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D (Excelencia / Generación de Conocimiento)
Año convocatoria 2014
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Unidad de gestión Secretaría de Estado de Educación, Formación Profesional y Universidades
Centro beneficiario CONSORCIO CENTRO DE INVESTIGACION BIOMEDICA EN RED M.P. (CIBER)
Identificador persistente http://dx.doi.org/10.13039/501100003329

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

B-cell leukemia transdifferentiation to macrophage involves reconfiguration of DNA methylation for long-range regulation

  • Bueno-Costa, Alberto
  • Piñeyro, David
  • Soler, Marta
  • Javierre, Biola M.
  • Raurell Vila, Helena
  • Subirana-Granés, Marc
  • Pasquali, Lorenzo
  • Martinez-Climent, Jose A.
  • Esteller, Manel
This work was supported by the Health Department PERIS-project no. SLT/002/16/00374 and AGAUR-projects no. 2017SGR1080, 2014SGR633, 2017SGR1033, and 2009SGR1315 of the Catalan Government (Generalitat de Catalunya); the Spanish Institute of Health Carlos III (ISCIII) project no. DTS16/00153, and CIBERONC CB16/12/00312 and CB16/12/00489; and Ministerio de Economía y Competitividad (MINECO) project nos. SAF2014-55000-R, BFU2014-57466-P, SAF2017-89673-R, SAF2017-86242-R, and SAF2015-70270-REDT cofinanced by the European Development Regional Fund, ‘A way to achieve Europe’ ERDF; the Cellex Foundation; and “la Caixa” Bank Foundation (LCF/PR/GN18/51140001). We thank Dr Thomas Graf for providing the transdifferentiation model.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Epigenetic loss of the endoplasmic reticulum-associated degradation inhibitor SVIP induces cancer cell metabolic reprogramming

  • Llinàs Arias, Pere
  • Moutinho, Catia
  • Esteller, Manel
The endoplasmic reticulum (ER) of cancer cells needs to adapt to the enhanced proteotoxic stress associated with the accumulation of unfolded, misfolded and transformation-associated proteins. One way by which tumors thrive in the context of ER stress is by promoting ER-Associated Degradation (ERAD), although the mechanisms are poorly understood. Here, we show that the Small p97/VCP Interacting Protein (SVIP), an endogenous inhibitor of ERAD, undergoes DNA hypermethylation-associated silencing in tumorigenesis to achieve this goal. SVIP exhibits tumor suppressor features and its recovery is associated with increased ER stress and growth inhibition. Proteomic and metabolomic analyses show that cancer cells with epigenetic loss of SVIP are depleted in mitochondrial enzymes and oxidative respiration activity. This phenotype is reverted upon SVIP restoration. The dependence of SVIP hypermethylated cancer cells on aerobic glycolysis and glucose was also associated with sensitivity to an inhibitor of the glucose transporter GLUT1. This could be relevant to the management of tumors carrying SVIP epigenetic loss, because these occur in high-risk patients who manifest poor clinical outcomes. Overall, our study provides insights into how epigenetics helps deal with ER stress and how SVIP epigenetic loss in cancer may be amenable to therapies that target glucose transporters., This work was supported by the Health Department PERIS project number SLT/002/16/00374 and AGAUR project numbers 2017SGR1080, 2014SGR633, 2017SGR1033, and 2009SGR1315 of the Catalan Government (Generalitat de Catalunya); the Spanish Institute of Health Carlos III (ISCIII) project number DTS16/00153 and Ministerio de Economía y Competitividad (MINECO) project numbers SAF2014-55000-R, BFU2014-57466-P, SAF2017-89673-R, and SAF2015-70270-REDT co-financed by the European Development Regional Fund, A way to achieve Europe ERDF; the Cellex Foundation; and “la Caixa” Bank Foundation (LCF/PR/PR15/11100003). MC acknowledges the prize “ICREA Academia” for excellence in research, funded by ICREA foundation. We thank the Scientific and Technological Centre (CCiTUB) of the University of Barcelona for technical support with cell cytometry and sorting. We also thank the Regenerative Medicine Center (CMRB) Electron Microscopy and Histology facility.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Essentiality of fatty acid synthase in the 2D to anchorage-independent growth transition in transforming cells

  • Bueno, María J.
  • Jimenez-Renard, Verónica
  • Samino-Gené, Sara
  • Capellades, Jordi
  • Junza, Alexandra
  • López-Rodríguez, María L.
  • Garcia-Carceles, Javier
  • López-Fabuel, Irene
  • Bolaños, Juan P.
  • Chandel, Navdeep S.
  • Yanes, Óscar
  • Colomer, Ramón
  • Quintela-Fandino, Miguel
Upregulation of fatty acid synthase (FASN) is a common event in cancer, although its mechanistic and potential therapeutic roles are not completely understood. In this study, we establish a key role of FASN during transformation. FASN is required for eliciting the anaplerotic shift of the Krebs cycle observed in cancer cells. However, its main role is to consume acetyl-CoA, which unlocks isocitrate dehydrogenase (IDH)-dependent reductive carboxylation, producing the reductive power necessary to quench reactive oxygen species (ROS) originated during the switch from two-dimensional (2D) to three-dimensional (3D) growth (a necessary hallmark of cancer). Upregulation of FASN elicits the 2D-to-3D switch; however, FASN's synthetic product palmitate is dispensable for this process since cells satisfy their fatty acid requirements from the media. In vivo, genetic deletion or pharmacologic inhibition of FASN before oncogenic activation prevents tumor development and invasive growth. These results render FASN as a potential target for cancer prevention studies., M.Q.F. is a recipient of the following grants: FIS PI13/00430 and FIS PI16/00354 funded by the Instituto de Salud Carlos III (ISCIII) and co-funded by the European Regional Development Fund (ERDF) and AECC Scientific Foundation (Beca de Retorno 2010). R.C. is a recipient of the following grants: FIS PI11/00832 and FIS PI14/00726 funded by the Instituto de Salud Carlos III (ISCIII) and co-funded by the European Regional Development Fund (ERDF), II14/00009 and PIE15/00068 from the Ministerio de Sanidad, Spain. N.S.C. is a recipient of an NIH grant (5R35CA197532). O.Y.T. is a recipient of the grants BFU2014-57466 from the Ministerio de Economía y Competitividad (MINECO). J.P.B. is funded by MINECO (SAF2016-78114-R), Instituto de Salud Carlos III (RD12/0043/0021), Junta de Castilla y León (Escalera de Excelencia CLU-2017-03), Ayudas Equipos Investigación Biomedicina 2017 Fundación BBVA, and Fundación Ramón Areces. This study was partially supported by the generous donations from Fundación CRIS Contra el Cáncer and AVON Spain. We thank Drs. Erwin Wagner and Nabil Djouder for their critical review of the paper.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

B-cell leukemia transdifferentiation to macrophage involves reconfiguration of DNA methylation for long-range regulation

  • Bueno-Costa, Alberto
  • Piñeyro, David
  • Soler, Marta
  • Javierre, Biola M.
  • Raurell Vila, Helena
  • Subirana-Granés, Marc
  • Pasquali, Lorenzo
  • Martinez-Climent, Jose A.
  • Esteller, Manel
This work was supported by the Health Department PERIS-project no. SLT/002/16/00374 and AGAUR-projects no. 2017SGR1080, 2014SGR633, 2017SGR1033, and 2009SGR1315 of the Catalan Government (Generalitat de Catalunya); the Spanish Institute of Health Carlos III (ISCIII) project no. DTS16/00153, and CIBERONC CB16/12/00312 and CB16/12/00489; and Ministerio de Economía y Competitividad (MINECO) project nos. SAF2014-55000-R, BFU2014-57466-P, SAF2017-89673-R, SAF2017-86242-R, and SAF2015-70270-REDT cofinanced by the European Development Regional Fund, ‘A way to achieve Europe’ ERDF; the Cellex Foundation; and “la Caixa” Bank Foundation (LCF/PR/GN18/51140001). We thank Dr Thomas Graf for providing the transdifferentiation model.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Epigenetic loss of the endoplasmic reticulum-associated degradation inhibitor SVIP induces cancer cell metabolic reprogramming

  • Llinàs Arias, Pere
  • Moutinho, Catia
  • Esteller, Manel
The endoplasmic reticulum (ER) of cancer cells needs to adapt to the enhanced proteotoxic stress associated with the accumulation of unfolded, misfolded and transformation-associated proteins. One way by which tumors thrive in the context of ER stress is by promoting ER-Associated Degradation (ERAD), although the mechanisms are poorly understood. Here, we show that the Small p97/VCP Interacting Protein (SVIP), an endogenous inhibitor of ERAD, undergoes DNA hypermethylation-associated silencing in tumorigenesis to achieve this goal. SVIP exhibits tumor suppressor features and its recovery is associated with increased ER stress and growth inhibition. Proteomic and metabolomic analyses show that cancer cells with epigenetic loss of SVIP are depleted in mitochondrial enzymes and oxidative respiration activity. This phenotype is reverted upon SVIP restoration. The dependence of SVIP hypermethylated cancer cells on aerobic glycolysis and glucose was also associated with sensitivity to an inhibitor of the glucose transporter GLUT1. This could be relevant to the management of tumors carrying SVIP epigenetic loss, because these occur in high-risk patients who manifest poor clinical outcomes. Overall, our study provides insights into how epigenetics helps deal with ER stress and how SVIP epigenetic loss in cancer may be amenable to therapies that target glucose transporters., This work was supported by the Health Department PERIS project number SLT/002/16/00374 and AGAUR project numbers 2017SGR1080, 2014SGR633, 2017SGR1033, and 2009SGR1315 of the Catalan Government (Generalitat de Catalunya); the Spanish Institute of Health Carlos III (ISCIII) project number DTS16/00153 and Ministerio de Economía y Competitividad (MINECO) project numbers SAF2014-55000-R, BFU2014-57466-P, SAF2017-89673-R, and SAF2015-70270-REDT co-financed by the European Development Regional Fund, A way to achieve Europe ERDF; the Cellex Foundation; and “la Caixa” Bank Foundation (LCF/PR/PR15/11100003). MC acknowledges the prize “ICREA Academia” for excellence in research, funded by ICREA foundation. We thank the Scientific and Technological Centre (CCiTUB) of the University of Barcelona for technical support with cell cytometry and sorting. We also thank the Regenerative Medicine Center (CMRB) Electron Microscopy and Histology facility.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

B-cell leukemia transdifferentiation to macrophage involves reconfiguration of DNA methylation for long-range regulation